Literature DB >> 9024930

Long duration-mild whole body hyperthermia of up to 12 hours in rats: feasibility, and efficacy on primary tumour and axillary lymph node metastases of a mammary adenocarcinoma: implications for adjuvant therapy.

H Matsuda1, F R Strebel, T Kaneko, L L Danhauser, G N Jenkins, N Toyota, J M Bull.   

Abstract

The feasibility and efficacy of low temperature (40 degrees C) long duration whole body hyperthermia (LL-WBH) was investigated in rats bearing a highly metastatic mammary adenocarcinoma (MTLn3). We compared the treatment effects of various durations of LL-WBH (40 degrees C for 2-12 h) to that of conventional short duration-high temperature WBH (SH-WBH, 41.5 degrees C for 2 h). SH-WBH, 2 h LL-WBH, and 4 h LL-WBH resulted in only modest primary tumour growth delays (TGDs) of 0.9, 1.1 and 1.8 d (days) respectively. In contrast, significantly increased TGDs of 2.8, 3.2, 2.6, and 3.1 d were achieved with 6, 8, 10 and 12 h LL-WBH, respectively (p < 0.05 compared to SH-WBH, 2 h-LL-WBH, and 4 h-LL-WBH). Notably, LL-WBH reduced the incidence of axillary lymph node metastasis at 14 days post-treatment, from 100% in normothermic controls and 92% after SH-WBH, to 33, 40, 50, and 60% following 4, 6, 8 and 10 h LL-WBH respectively. When the duration of LL-WBH was extended to 12 h, no reduction in axillary lymph node metastasis was observed. Normal tissue toxicity of LL-WBH appeared to be minimal and LL-WBH durations of up to 12 h were well tolerated. These data show that LL-WBH for durations of from 4 to 10 h has greater antitumour activity than SH-WBH, against mammary adenocarcinoma, suggesting that LL-WBH may have therapeutic potential in the treatment of malignant disease.

Entities:  

Mesh:

Year:  1997        PMID: 9024930     DOI: 10.3109/02656739709056433

Source DB:  PubMed          Journal:  Int J Hyperthermia        ISSN: 0265-6736            Impact factor:   3.914


  3 in total

1.  An important role for granulocytes in the thermal regulation of colon tumor growth.

Authors:  Julie R Ostberg; Bradley R Ertel; Julie A Lanphere
Journal:  Immunol Invest       Date:  2005       Impact factor: 3.657

2.  Fever-range whole body thermotherapy combined with oxaliplatin: a curative regimen in a pre-clinical breast cancer model.

Authors:  R Wanda Rowe; Frederick R Strebel; Jesse M Proett; Wanleng Deng; Diana Chan; Guangan He; Zahid Siddik; Joan M C Bull
Journal:  Int J Hyperthermia       Date:  2010       Impact factor: 3.914

3.  Characterization of mild whole-body hyperthermia protocols using human breast, ovarian, and colon tumors grown in severe combined immunodeficient mice.

Authors:  E A Repasky; E Tims; M Pritchard; R Burd
Journal:  Infect Dis Obstet Gynecol       Date:  1999
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.